HCA Healthcare experienced a strong rebound in demand after the pandemic effects moderated, with COVID admissions dropping to 3% in the second quarter. Volume growth across all categories exceeded pre-pandemic levels, supported by an improved payer mix driven by commercial volumes. Revenues grew 30% to $14.4 billion, with inpatient revenues increasing 20% and outpatient revenues soaring by 59%. Adjusted EBITDA margin improved year-over-year and sequentially, and diluted earnings per share excluding certain items increased 35%. The company raised its annual guidance to reflect its strong performance, expecting adjusted EBITDA in the range of $12.1 billion to $12.5 billion and diluted earnings per share between $16.30 and $17.10. HCA Healthcare also continues to invest in its strategic plan, including new clinical capabilities, enterprise resources, and regional expansions through acquisitions and capital projects.